161 related articles for article (PubMed ID: 22289993)
1. Outcome of patients with relapsed or refractory chronic lymphocytic leukemia treated with flavopiridol: impact of genetic features.
Woyach JA; Lozanski G; Ruppert AS; Lozanski A; Blum KA; Jones JA; Flynn JM; Johnson AJ; Grever MR; Heerema NA; Byrd JC
Leukemia; 2012 Jun; 26(6):1442-4. PubMed ID: 22289993
[No Abstract] [Full Text] [Related]
2. Flavopiridol in the treatment of chronic lymphocytic leukemia.
Christian BA; Grever MR; Byrd JC; Lin TS
Curr Opin Oncol; 2007 Nov; 19(6):573-8. PubMed ID: 17906454
[TBL] [Abstract][Full Text] [Related]
3. Chronic lymphocytic leukemia and treatment resistance in cancer: the role of the p53 pathway.
Zenz T; Benner A; Döhner H; Stilgenbauer S
Cell Cycle; 2008 Dec; 7(24):3810-4. PubMed ID: 19098429
[TBL] [Abstract][Full Text] [Related]
4. Imperfect correlation between p53 dysfunction and deletion of TP53 and ATM in chronic lymphocytic leukaemia.
Carter A; Lin K; Sherrington PD; Atherton M; Pearson K; Douglas A; Burford A; Brito-Babapulle V; Matutes E; Catovsky D; Pettitt AR
Leukemia; 2006 Apr; 20(4):737-40. PubMed ID: 16437137
[No Abstract] [Full Text] [Related]
5. Mutation status of the residual ATM allele is an important determinant of the cellular response to chemotherapy and survival in patients with chronic lymphocytic leukemia containing an 11q deletion.
Austen B; Skowronska A; Baker C; Powell JE; Gardiner A; Oscier D; Majid A; Dyer M; Siebert R; Taylor AM; Moss PA; Stankovic T
J Clin Oncol; 2007 Dec; 25(34):5448-57. PubMed ID: 17968022
[TBL] [Abstract][Full Text] [Related]
6. The potential anticancer agent PK11195 induces apoptosis irrespective of p53 and ATM status in chronic lymphocytic leukemia cells.
Santidrián AF; Cosialls AM; Coll-Mulet L; Iglesias-Serret D; de Frias M; González-Gironès DM; Campàs C; Domingo A; Pons G; Gil J
Haematologica; 2007 Dec; 92(12):1631-8. PubMed ID: 18055986
[TBL] [Abstract][Full Text] [Related]
7. Complex karyotype is a stronger predictor than del(17p) for an inferior outcome in relapsed or refractory chronic lymphocytic leukemia patients treated with ibrutinib-based regimens.
Thompson PA; O'Brien SM; Wierda WG; Ferrajoli A; Stingo F; Smith SC; Burger JA; Estrov Z; Jain N; Kantarjian HM; Keating MJ
Cancer; 2015 Oct; 121(20):3612-21. PubMed ID: 26193999
[TBL] [Abstract][Full Text] [Related]
8. Mutations in the ATM gene lead to impaired overall and treatment-free survival that is independent of IGVH mutation status in patients with B-CLL.
Austen B; Powell JE; Alvi A; Edwards I; Hooper L; Starczynski J; Taylor AM; Fegan C; Moss P; Stankovic T
Blood; 2005 Nov; 106(9):3175-82. PubMed ID: 16014569
[TBL] [Abstract][Full Text] [Related]
9. A novel functional assay using etoposide plus nutlin-3a detects and distinguishes between ATM and TP53 mutations in CLL.
Best OG; Gardiner AC; Majid A; Walewska R; Austen B; Skowronska A; Ibbotson R; Stankovic T; Dyer MJ; Oscier DG
Leukemia; 2008 Jul; 22(7):1456-9. PubMed ID: 18200038
[No Abstract] [Full Text] [Related]
10. [Gene atm and chronic lymphocytic leukemia - review].
Zhu DX; Xu W; Li JY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Oct; 16(5):1242-6. PubMed ID: 18928637
[TBL] [Abstract][Full Text] [Related]
11. Flavopiridol induces apoptosis in chronic lymphocytic leukemia cells via activation of caspase-3 without evidence of bcl-2 modulation or dependence on functional p53.
Byrd JC; Shinn C; Waselenko JK; Fuchs EJ; Lehman TA; Nguyen PL; Flinn IW; Diehl LF; Sausville E; Grever MR
Blood; 1998 Nov; 92(10):3804-16. PubMed ID: 9808574
[TBL] [Abstract][Full Text] [Related]
12. Variations of the ataxia telangiectasia mutated gene in patients with chronic lymphocytic leukemia lack substantial impact on progression-free survival and overall survival: a Cancer and Leukemia Group B study.
Lozanski G; Ruppert AS; Heerema NA; Lozanski A; Lucas DM; Gordon A; Gribben JG; Morrison VA; Rai KM; Marcucci G; Larson RA; Byrd JC
Leuk Lymphoma; 2012 Sep; 53(9):1743-8. PubMed ID: 22369572
[TBL] [Abstract][Full Text] [Related]
13. [Prognostic significance of p53 and ATM gene deletion in patients with chronic lymphocytic leukemia].
Xu W; Li JY; Li L; Wu YJ; Yu H; Shen QD; Qiu HX
Zhonghua Xue Ye Xue Za Zhi; 2008 Jul; 29(7):450-3. PubMed ID: 19035176
[TBL] [Abstract][Full Text] [Related]
14. Biallelic ATM inactivation significantly reduces survival in patients treated on the United Kingdom Leukemia Research Fund Chronic Lymphocytic Leukemia 4 trial.
Skowronska A; Parker A; Ahmed G; Oldreive C; Davis Z; Richards S; Dyer M; Matutes E; Gonzalez D; Taylor AM; Moss P; Thomas P; Oscier D; Stankovic T
J Clin Oncol; 2012 Dec; 30(36):4524-32. PubMed ID: 23091097
[TBL] [Abstract][Full Text] [Related]
15. ATM gene alterations in chronic lymphocytic leukemia patients induce a distinct gene expression profile and predict disease progression.
Guarini A; Marinelli M; Tavolaro S; Bellacchio E; Magliozzi M; Chiaretti S; De Propris MS; Peragine N; Santangelo S; Paoloni F; Nanni M; Del Giudice I; Mauro FR; Torrente I; Foà R
Haematologica; 2012 Jan; 97(1):47-55. PubMed ID: 21993670
[TBL] [Abstract][Full Text] [Related]
16. Flavopiridol treatment of patients aged 70 or older with refractory or relapsed chronic lymphocytic leukemia is a feasible and active therapeutic approach.
Stephens DM; Ruppert AS; Blum K; Jones J; Flynn JM; Johnson AJ; Ji J; Phelps MA; Grever MR; Byrd JC
Haematologica; 2012 Mar; 97(3):423-7. PubMed ID: 22271900
[TBL] [Abstract][Full Text] [Related]
17. New translocations in a case of atypical B-cell chronic lymphocytic leukemia: involvement of ATM, MLL, and TP53 genes.
Collado R; Hueso J; Cabello AI; Oliver I; Egea M; Orero M; Miguel-Sosa A; Cigudosa JC; Benítez J; Barragán E; Carbonell F
Cancer Genet Cytogenet; 2006 Sep; 169(2):176-8. PubMed ID: 16938579
[No Abstract] [Full Text] [Related]
18. Prognostic significance of ATM and TP53 deletions in Chinese patients with chronic lymphocytic leukemia.
Xu W; Li JY; Wu YJ; Yu H; Shen QD; Li L; Fan L; Qiu HX
Leuk Res; 2008 Jul; 32(7):1071-7. PubMed ID: 18035414
[TBL] [Abstract][Full Text] [Related]
19. Inactivation of p53 and deletion of ATM in B-CLL patients in relation to IgVH mutation status and previous treatment.
Trbusek M; Malcikova J; Smardova J; Kuhrova V; Mentzlova D; Francova H; Bukovska S; Svitakova M; Kuglik P; Linkova V; Doubek M; Brychtova Y; Zacal J; Kujickova J; Pospisilova S; Dvorakova D; Vorlicek J; Mayer J
Leukemia; 2006 Jun; 20(6):1159-61. PubMed ID: 16572201
[No Abstract] [Full Text] [Related]
20. Toward a comprehensive prognostic scoring system in chronic lymphocytic leukemia based on a combination of genetic parameters.
Haferlach C; Dicker F; Weiss T; Schnittger S; Beck C; Grote-Metke A; Oruzio D; Kern W; Haferlach T
Genes Chromosomes Cancer; 2010 Sep; 49(9):851-9. PubMed ID: 20552631
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]